Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

| More on:
Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investment outfit Wilson Asset Management (WAM) is always on the hunt for undervalued growth shares. Which might be why ASX healthcare share Sigma Healthcare Ltd (ASX: SIG) is a pick inside one of WAM's listed investment companies (LICs).

A LIC invests in shares/assets that it believes can produce good returns for shareholders, and WAM Research Limited (ASX: WAX) has a deep research process to find such opportunities. It looks at factors like free cash flowreturn on equity (ROE), meeting management, and a company's overall quality.

On paper, Sigma may not sound like a rapidly growing business. It describes itself as a leading Australian full-line wholesale and distribution business to pharmacies. It has retail pharmacy brands, including Amcal and Discount Drug Stores, as well as an independent offering called PriceSave.

But there's one key reason why WAM likes the ASX healthcare shares so much.

Potential merger with Chemist Warehouse

Sigma is currently attempting to merge with Chemist Warehouse, the biggest pharmacy business in Australia.

Combining the two companies would lead to significant scale, adding revenue and cost synergies. A combined business would have the potential to generate much bigger profits than if the two companies stayed separate.

The Australian Competition and Consumer Commission (ACCC) is considering this proposed merger carefully because it could reduce competition in the pharmacy space.

The ACCC said it had concerns, including "the potential harm to pharmacies currently supplied by Sigma and the potential for Chemist Warehouse to access these pharmacies' data in ways that damage competition".

However, Sigma recently offered a number of court-enforceable undertakings to attempt to allay the ACCC's fears.

WAM noted that despite the ongoing regulatory process, the market appeared more confident that the proposed merger with Chemist Warehouse would be approved.

The investment team said the Chemist Warehouse management remained confident in its ability to expand in Australia and overseas.

If the merger does get the go-ahead, the WAM team is "excited at the prospect of owning one of the country's best retailers with a global store roll-out on the horizon".

What will the ASX healthcare share do to get the deal across the line?

Sigma's undertakings include not preventing or hindering franchisees who entered into their franchising arrangements before 1 January 2024 from terminating their franchise agreements with Sigma for a period of three years.

Next, it would place restrictions on the collection, use and disclosure of confidential data and information from Sigma's wholesale customers and customers for a period of three years.

Finally, Sigma would also remain a participating pharmaceutical wholesale under the Commonwealth Government's Community Service Obligation (CSO) arrangements for at least five years.

The ACCC is seeking feedback about these moves to address competition concerns, and it continues to investigate the impact of the proposed acquisition.

Sigma Healthcare share price snapshot

The company's stock has climbed a hefty 85% since the start of 2024, as shown in the chart below.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »